Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;11(3):185-98.
doi: 10.1111/j.1476-5829.2011.00311.x. Epub 2012 Feb 28.

Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma

J W Elliott  1 , P Cripps, A M Marrington, I A Grant, L Blackwood
Affiliations

Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma

J W Elliott et al. Vet Comp Oncol. 2013 Sep.

Abstract

The aim of the study was to report the outcome of treatment of 97 dogs with lymphoma that received a multi-agent chemotherapy protocol containing epirubicin as the primary anthracycline. Seventy-five dogs received a 25-week protocol with no maintenance phase whilst 22 dogs received a maintenance phase. Complete response rate was 96% and time to first relapse (TTR) and overall survival (OS) time for all dogs were 216 and 342 days, respectively. Dogs with T-cell lymphoma and those classified as WHO substage b had significantly poorer OS times and TTR. The protocol was well tolerated with toxicity similar to doxorubicin-containing protocols. Epirubicin as part of a multi-agent protocol is safe and effective in the treatment of canine multicentric lymphoma. There is a high initial response rate and an overall median survival time that is similar to other published doxorubicin-containing protocols.

Keywords: CEOP; anthracycline; canine; chemotherapy; epirubicin; lymphoma.

PubMed Disclaimer

MeSH terms